anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses riboflavin derivatives, and a process of preparing the same, and their applications. The water in oil suspending preparation of the riboflavin derivatives has high stability, and the effects could last for 3 months after intramuscular injection at dose of 150mg. This invention increases significantly the bioavailability of riboflavin in vivo, and provides an important treatment method for cure of ariboflavinosis. The preparation is found to have remarkable effect on dermatitis, oral and digestive tract catarrhs caused by bone marrow transplantation for leukemia and chemotherapy for tumor. It is also found to have noticeable effect on persistent oral ulcer, and enhance the tolerability to chemotherapy and radiotherapy. In the treatment of coronary heart disease and hypertension syndrome, arthritis and burn wound, the preparation also has significant effects. This invention has a wide application perspective for its simple techniques, definite long-acting action and effectiveness.
This is a prospective, international, multicenter outcome cohort study. This study starts at the moment patients visit the outpatient clinic 3 to 6 months after a diagnosis of acute PE as part of routine medical care. If patients consent to study participation, the CTEPH clinical prediction score will be calculated. This score consists of 6 variables that should be assessed at the time of PE diagnosis: unprovoked PE (+6 points), known hypothyroidism (+3 points), diagnostic delay \>2 weeks (+3 points), right ventricular dysfunction on computed tomography pulmonary angiography (CTPA) or echocardiography (+2 points), known diabetes mellitus (-3 points) and thrombolytic therapy or embolectomy for the acute PE event (-3 points) CTEPH is considered to be not present in patients with a low probability (≤6 points) and no symptoms suggestive of CTEPH, i.e. dyspnea on exertion, edema, newly developed palpitations, syncope or chest pains. The remaining patients with either high probability (\>6 points) or who report symptoms that may be associated with CTEPH will be subjected to the 'rule-out criteria'. CTEPH will be assumed not present in patients with an age- and gender dependent normal NT-proBNP level (as defined by the assay's manufacturer), in the absence of these 3 ECG criteria: 1) rSR' or rSr' pattern in lead V1, 2) R:S \>1 in lead V1 with R \>0.5mV and 3) QRS axis \>90o. Patients who have an abnormal result from the 'rule-out criteria' will be referred for transthoracic echocardiography. All echocardiograms will be judged by the echocardiographic criteria for suspected PH according to the 2015 ESC guidelines.

In case of echocardiographic intermediate or high probability of PH, patients will be referred for further diagnostic work-up of suspected CTEPH starting with perfusion lung scan or VQ-scan and right heart catheterization, of which the results will be discussed by an independent interdisciplinary working group of PH specialists, to ensure optimal diagnostic management. This latter diagnostic work-up of an abnormal echocardiograph lies within the setting of standard medical care.

All patients who were not diagnosed with pulmonary hypertension of any origin, or with NYHA class III or IV heart failure due to left ventricular systolic dysfunction, left ventricular diastolic dysfunction or significant valvular lesions, will be followed for a total of 2 years from the index PE diagnosis. During that period, the study protocol will not interfere with standard patient care, allowing diagnostic tests as deemed indicated by the treating physician including echocardiography in case of new respiratory symptoms. At the end of the follow-up period, all patients will be subjected to a second echocardiography that will be handled according to the above stated procedures to evaluate the presence of CTEPH.
PURPOSE:A cosmetic, containing a crosslinked proteinaceous high polymer obtained by reacting transglutaminase with protein in a liquid, and having good humectant property and remarkably improved extensibility. CONSTITUTION:A cosmetic obtained by incorporating a crosslinked high polymer prepared by reacting transglutaminase with protein, e.g. vegetable protein such as defatted oil seed, or animal protein such as milk protein or gelatin collagen, in the form of a mixture with water, oil-in-water type or water-in-oil type emulsion to give a highly viscous material or gelatinous material when the liquid contains >=2wt%, preferably >=5wt% protein or solutional material when the liquid contains <=2wt% protein with a cosmetic, etc. The amount of the crosslinked high polymer is 5-10% expressed in terms of dry material. The crosslinked high polymer incorporated with the cosmetic imparts moderate moisture to the skin or hair, and the skin or hair surface can be protected. EFFECT:Stable with prolonged action.
PURPOSE:To increase the stability of aq. high viscosity gel by stirring an aq. soln. contg. both the quaternary ammonium salt shown by the specified chemical formula and higher alcohol shown by the specified chemical formula in the specified temp. conditions. CONSTITUTION:An aq. soln. contg. one or more kinds of the quaternaly ammo nium salt shown by a formula I and one or more kinds of higher alcohol shown by a formua II is manufactured wherein R1 shows 10-22C alkyl group, R2 and R3 show 1-3C alkyl group, R4 shows 1-3C alkyl group and benzyl group and X shows Cl atom and C atom and R5 shows 12-22C alkyl group. An aq. high viscosity gel is manufactured by stirring the aq. soln. at the temp. which is lower than the phase transition temp. changing till (30-90 deg.C) by means of the kind and the combination of the salt of the formula I and the alcohol of the formula II and more than m.p. of higher alcohol.
PROBLEM TO BE SOLVED: To obtain a gel preparation composition which contains a hydrophilic copolymer of a specific structure, a polyhydric alcohol and a physiologically active substance and is prepared by crosslinking its hydrophilic copolymer, thus manifests excellent transdermal absorption. SOLUTION: This composition contains (A) a hydrophilic copolymer comprising (i) 10-90wt.% of a monomer unit bearing a carboxyl group, preferably (meth) acrylic acid and (ii) 90-10wt.% of other copolymerizable monomers, (B) a polyhydric alcohol and (C) a pharmacologically active substance, preferably at least one selected from progesterone, estradiol, testosterone, pindolol, clonidine, lidocaine and nifedipine and the component A is crosslinked. This composition is laminated to give a gel preparation. The amount of the component B is preferably 50-500 pts.wt., more preferably 100-400 pts.wt. per 100 pts.wt. of the component A, while the component C is preferably 5-100 pts.wt., more preferably 20-70 pts.wt.
The invention provides a series of aryl and heterocycle substituted imidazole, oxazole and thiazole derivatives, particularly stilbene tumor targeted medicine Combretastatin A4 analogs. The natural product Combretastatin A4 is used as a lead compound, and imidazole, oxazole and thiazole quinary heterocycles are substituted for vinyl chains in the structure to obtain a series of imidazole, oxazole and thiazole Combretastatin A4 analogs. The invention overcomes the defect that the vinyl group in the Combretastatin A4 structure can be easily isomerized. The stilbene tumor targeted medicine Combretastatin A4 analogs are a type of compounds in a brand new structure. The initial pharmacological activity screening test indicates that most compounds have a function on inhibiting proliferation of tumor cells in vitro, part of compounds have an obvious function on inhibiting proliferation, and IC50 is equivalent to CA4, reaching Grade nM. The aryl and heterocycle substituted imidazole, oxazole and thiazole Combretastatin A4 analogs and salts thereof are applicable to preparation of antineoplastic drugs.
The increasing ubiquity of data in everyday life has elevated the importance of data literacy and accessible data representations, particularly for individuals with disabilities. While prior research predominantly focuses on the needs of the visually impaired, our survey aims to broaden this scope by investigating accessible data representations across a more inclusive spectrum of disabilities. After conducting a systematic review of 152 accessible data representation papers from ACM and IEEE databases, we found that roughly 78% of existing articles center on vision impairments. In this article, we conduct a comprehensive review of the remaining 22% of papers focused on underrepresented disability communities. We developed categorical dimensions based on accessibility, visualization, and human-computer interaction to classify the papers. These dimensions include the community of focus, issues addressed, contribution type, study methods, participants involved, data type, visualization type, and data domain. Our work redefines accessible data representations by illustrating their application for disabilities beyond those related to vision. Building on our literature review, we identify and discuss opportunities for future research in accessible data representations.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with HEPSERA.

Adverse reactions to HEPSERA identified from placebo-controlled and open label studies include the following: asthenia, headache, abdominal pain, diarrhea, nausea, dyspepsia, flatulence, increased creatinine, and hypophosphatemia.

The incidence of these adverse reactions in studies 437 and 438, where 522 patients with chronic hepatitis B and compensated liver disease received double-blind treatment with HEPSERA (n=294) or placebo (n=228) for 48 weeks is presented in Table 2. Patients who received open-label HEPSERA for up to 240 weeks in Study 438 reported adverse reactions similar in nature and severity to those reported in the first 48 weeks.

No patients treated with HEPSERA developed a confirmed serum creatinine increase ≥0.5 mg/dL or confirmed phosphorus decrease ≤2 mg/dL from baseline by Week 48. By Week 96, 2% of HEPSERA-treated patients, by Kaplan-Meier estimate, had increases in serum creatinine ≥0.5 mg/dL from baseline (no placebo-controlled results were available for comparison beyond Week 48). For patients who chose to continue HEPSERA for up to 240 weeks in Study 438, 4 of 125 patients (3%) had a confirmed increase of 0.5 mg/dL from baseline. The creatinine elevation resolved in 1 patient who permanently discontinued treatment and remained stable in 3 patients who continued treatment. For 65 patients who chose to continue HEPSERA for up to 240 weeks in Study 437, 6 had a confirmed increase in serum creatinine of ≥0.5 mg/dL from baseline with 2 patients discontinuing from the study due to the elevated serum creatinine concentration. See Adverse Reactions (6.2) for changes in serum creatinine in patients with underlying renal insufficiency at baseline.
Low temperature is a common stress source for the poultry industry in the north of China. However, the low energy consuming and economical way to reduce the negative effects from cold stress is still limited. Therefore, the aim of this study was to investigate the effect of rutin on intestinal barrier in mice under low temperature. The cold stress model was established at 4°C for 3 h each day and the experiment lasted for 21 days. Forty Balb/c mice were randomly divided into four treatments: CON, normal temperature with the basal diet; RUT, normal temperature with the basal diet +150 mg/kg body weight (BW) of rutin; CS, mice under cold stress with basal diet; CR, 150 mg/kg of BW rutin under cold stress. Rutin supplementation significantly increased the ileum villus-to-crypt ratio compared with these non-supplemented treatments. Rutin attenuated the hypothermia induced morphological damage in the ileum. In addition, rutin improved the antioxidant capacity of mice under cold stress. Rutin supplementation significantly increased the trypsin activity and inhibited the lipase in cold stressed mice. Rutin supplementation significantly inhibited the production of inflammatory factors induced by cold stress. Rutin induced the inhibition of TLR4 and NF-кB, thereby reducing the expression of inflammation-related genes. In addition, rutin improved the reduction of the intestinal claudin-1 and occludin expression in those mice in the cold stress (P < .05) and improved the intestinal ZO-1 expression in cold stressed mice. Finally, rutin alleviated the dysregulation of intestinal microflora in the mice under cold stress.
<P>PROBLEM TO BE SOLVED: To provide a novel extraction method wherein ginseng saponins are converted into saponins unique to red ginseng and extracted.  <P>SOLUTION: The method comprises a step of pressurizing and heating water or 1-6C alcohol to produce a high-pressure liquid solvent and a step of treating ginseng with the solvent to extract saponins. Alternatively, the method for converting the saponins in ginseng into the saponins unique to red ginseng and extracting the same comprises a step of extracting the saponins through acid treatment or treatment with a mixture of alcohol and acid. The method enables effective extraction of saponins and also enables extraction of ginsenosides Rg<SB>3</SB>and Rh<SB>2</SB>, compound K and PPD from ginseng lacking the saponins unique to red ginseng, e.g. ginsenosides Rg<SB>3</SB>, Rh<SB>2</SB>, etc., by producing the unique saponins through conversion. The extraction method is a batch-type method which enables easy extraction of saponins and can be used for more efficient, more economical production of an extract of the saponins unique to red ginseng.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention discloses a fumigating and washing liquid for treating itching in head. The fumigating and washing liquid is composed of the following traditional Chinese medicinal materials by weight: 20-30g of radix angelicae, 20-30g of angelica, 15-20g of kuh-seng, 10-15g of radix ligustici sinensis, 10-15g of chuanxiong rhizome and 8-12g of fructus cnidii. The traditional Chinese medicinal materials are decocted with water to obtain a liquid medicine for repeatedly fumigating and washing the itching part of the scalp, and thus the liquid medicine can fully penetrate into the scalp. All traditional Chinese medicinal materials are blended to achieve the effects of expelling wind and removing cold, tonifying the blood and removing blood stasis as well as dredging collaterals and relieving itching. The fumigating and washing liquid can relieve itching and also can effectively inhibit the growth of dandruff. The fumigating and washing liquid is completely composed of Chinese herbal medicines and does not contain hormone medicines, so that the fumigating and washing liquid is free of toxic or side effect on the human body; and the fumigating and washing liquid is convenient to use, low in cost and wide in range of application. The obvious effective rate is 65%, and the total effective rate is 85%.
The ability to respond to a polysaccharide vaccine antigen is an integral part of evaluating a patient with immunodeficiency. The pneumococcal vaccine (Pneumovax ®) remains the only readily available and the most widely used unconjugated polysaccharide vaccine. Although the pneumococcal vaccine is widely used test the immune systems response to a polysaccharide antigen, no clear guidelines or studies exist to what is considered a proper response to the Pneumovax ®. Immunoglobulin M (IgM) memory B cells are thought to play an important role in protection against pneumococcal disease. It is not known to what extent the ability of B cells to be activated in response to pneumococcal vaccination contributes to protective immunity. To address these issues, the following two specific aims are proposed:

Specific Aim 1. Assess Immunoglobulin G (IgG) antibodies to pneumococcus pre- and post-pneumococcal immunization in healthy controls Specific Aim 2. Analysis of B cell subsets in blood of healthy controls pre-and post-pneumococcal immunization to identify changes in memory B cell, class switched and activated B cells.
Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
PURPOSE:To obtain a remedy for pollinosis by mixing components extracted from Adenophora triphylla A. DC. with vitamin B1. CONSTITUTION:Pollinosis can be readily remedied by administration of a mixture of components extracted from Adenophora triphylla A. DC. including varieties and vitamin B1. A mixture prepared by adding ethyl alcohol to the above- mentioned mixture of the components extracted from Adenophora triphylla A. DC. and vitamin B1 is also useful. Drug efficiency is obtained by 2-4 times administration every day during suffering from pollinosis.
PURPOSE: A pharmaceutical composition containing cordycepin is provided to induce long sleeping and to increase total sleeping time. CONSTITUTION: A pharmaceutical composition for treating insomnia contains Cordyceps militaris extract as an active ingredient. The extract is a crude extract or non-polar solvent soluble extract. The pharmaceutical composition also contains cordycepin of chemical formula 1 as an active ingredient. The cordycepin is isolated from Cordyceps militaris. A health functional food for treating insomnia contains Cordyceps militaris extract or cordycepin isolated from the extract as an active ingredient. The health functional food is powder, granule, tablet, capsule, or beverage.
<P>PROBLEM TO BE SOLVED: To provide an anti-oxidizing raw material which can exhibit a high anti-oxidizing action, to provide a food or drink, and to provide a method for producing a lignan compound, by which the lignan compound can easily be produced by the fermentation technique.  <P>SOLUTION: This anti-oxidizing raw material is obtained by inoculating a fermentation raw material containing sesamin, sesaminol or a sesaminol glycoside with a microorganism belonging to the genus Aspergillus to subject the raw material to a microorganism fermentation treatment. It is preferable that the anti-oxidizing raw material contains a sesamin dicatechol-form compound or a sesaminol catechol-form compound. It is more preferable that a sesamin catechol-form compound, a sesamin dicatechol-form compound or a sesaminol catechol-form compound is contained as a lignan compound in a larger amount than the fermentation raw material. It is preferable that the fermentation raw material is sesame seeds, roasted sesame, roasted sesame oil, un-roasted sesame salad oil, sesame strained lees, or sesame deodorized scum. A health food as the food or drink contains the anti-oxidizing raw material.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
FIELD: biotechnology; genetic engineering.SUBSTANCE: recovered AAV capsid protein contains a sequence selected from the group consisting of: SEQ ID NO: from 51 to 61. Recombinant expression vector contains a nucleic acid sequence coding the isolated capsid AAV protein. Composition for transgene delivery to the patient contains isolated capsid AAV protein and a pharmaceutically acceptable carrier. Recombinant AAV (rAAV) contains extracted capsid AAV protein. Composition for transgene delivery to a patient comprises recombinant rAAV and a pharmaceutically acceptable carrier. Method for delivering a transgene to a patient comprises administering rAAV to a patient, wherein rAAV contains at least one transgene and in which rAAV infects target tissue cells. Method for creating a somatic transgenic animal model involves administering recombinant rAAV to an animal other than a human, wherein rAAV contains at least one transgene and in which rAAV infects a cell of a target tissue of an animal other than a human. Kit for producing rAAV contains a container containing recombinant AAV having an isolated capsid AAV protein.EFFECT: group of inventions provides improved properties of tissue tropism.16 cl, 4 dwg, 5 tbl, 1 ex
BACKGROUND: Sepsis remains a crucial global health issue characterized by high mortality rates and a lack of specific treatments. This study aimed to elucidate the molecular mechanisms underlying sepsis and to identify potential therapeutic targets and compounds.
METHODS: High-throughput sequencing data from the GEO database (GSE26440 as the training set and GSE13904 and GSE32707 as the validation sets), weighted gene co-expression network analysis (WGCNA), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, alongside a combination of PPI and machine learning methods (LASSO and SVM) were utilized.
RESULTS: WGCNA identified the black module as positively correlated, and the green module as negatively correlated with sepsis. Further intersections of these module genes with age-related genes yielded 57 sepsis-related genes. GO and KEGG pathway enrichment analysis, PPI, LASSO, and SVM selected six hub aging-related genes: BCL6, FOS, ETS1, ETS2, MAPK14, and MYC. A diagnostic model was constructed based on these six core genes, presenting commendable performance in both the training and validation sets. Notably, ETS1 demonstrated significant differential expression between mild and severe sepsis, indicating its potential as a biomarker of severity. Furthermore, immune infiltration analysis of these six core genes revealed their correlation with most immune cells and immune-related pathways. Additionally, compounds were identified in the traditional Chinese medicine Danshen, which upon further analysis, revealed 354 potential target proteins. GO and KEGG enrichment analysis of these targets indicated a primary enrichment in inflammation and immune-related pathways. A Venn diagram intersects these target proteins, and our aforementioned six core genes yielded three common genes, suggesting the potential efficacy of Danshen in sepsis treatment through these genes.
CONCLUSIONS: This study highlights the pivotal roles of age-related genes in the molecular mechanisms of sepsis, offers potential biomarkers, and identifies promising therapeutic compounds, laying a robust foundation for future studies on the treatment of sepsis.
The societal hallmark of the Covid-19 pandemic was a set of mitigation measures such as lockdowns and curfews. The cognitive impact on the public of the resulting spatial, social and temporal constraints is still being investigated. While pandemic time has been extensively studied and mostly described as slowed down and elongated, opposite experimental patterns across national and social contexts leave open an important explanatory gap in order to understand which factor has been causally fundamental in determining the phenomenology of the crisis. In this paper, we use a quantitative questionnaire developed for measuring temporal and social disorientation on a sample of 3306 respondents during an acute phase of restrictions in France. We show that social disorientation greatly contributed to the temporal disruptions experienced during the pandemic. This result reinforces the importance for public authorities to address the compounding effect of feeling isolated during crises.